cagrilintide news 2025 VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes REDEFINE trials advance combination treatment
REDEFINE trials advance combination treatment for weight management ADA Meeting News Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide 10mg Valar Peptides
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



